Trial Profile

Evaluation of Clinicopathological Factors in Patients with Resected Stage I-IIIA Breast Cancer (N-SAS-BC 01/CUBC Biomarker Study)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 30 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tegafur/uracil (Primary) ; Cyclophosphamide; Fluorouracil; Methotrexate
Indications Breast cancer
Focus Biomarker; Therapeutic Use

Most Recent Events

22 Jan 2020 New trial record
14 Dec 2019 Results of this long-term follow-up study using randomized controlled trials (N-SAS-BC01 and CUBC trials) comparing the efficacy of oral tegafur-uracil with CMF presented at the 42nd Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com